Comparing pain relief methods after hip surgery
Efficacy of Combined Nalbuphine-bupivacaine Versus Dexamethasone-bupivacaine in Pericapsular Nerve Group Block (PENG) for Postoperative Analgesia in Hip Surgeries: A Randomized Clinical Study
This study is testing two different pain relief methods after hip surgery to see which one helps patients feel better and need less extra medication.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 102 (estimated) |
| Ages | 21 Years to 65 Years |
| Sex | All |
| Sponsor | Zagazig University Government |
| Locations | 1 site (Zagazig) |
| Trial ID | NCT06972654 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of two different analgesic combinations, nalbuphine-bupivacaine and dexamethasone-bupivacaine, in providing pain relief through an ultrasound-guided pericapsular nerve group (PENG) block for patients undergoing hip surgeries. It aims to measure the time until the first request for additional pain relief, the total amount of rescue analgesics used, and the pain scores during rest and movement. Additionally, the study will assess any side effects related to the drugs or the nerve block procedure, as well as patient satisfaction and ease of spinal positioning.
Who should consider this trial
Good fit: Ideal candidates are adults aged 21-64 with a BMI of 25-30 undergoing unilateral hip surgery under spinal anesthesia.
Not a fit: Patients with severe cardiovascular, respiratory, renal, or hepatic conditions, or those on chronic opioid therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved pain management and reduced opioid use for patients after hip surgeries.
How similar studies have performed: Other studies have shown promising results with similar analgesic approaches, indicating potential for success in this study.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * Patients acceptance. * Age: Adults aged 21-64 years old. * BMI: 25-30 kg/m2 * Sex: both sexes (males or females). * Patients undergoing unilateral hip surgery under spinal anesthesia. * ASA (American Society of Anesthesiologists) physical status classification I to II. \*Exclusion criteria: * Patients with contraindications to regional anesthesia (e.g. local or systemic infections, or severe neurological or muscular disorders or patient on anticoagulant). * Allergy to study drugs: bupivacaine or nalbuphine or dexamethasone * Patients with severe cardiovascular, respiratory, renal, or hepatic conditions, uncontrolled diabetes diseases, or those undergoing chronic opioid therapy. * Psychiatric disorders that hinder informed consent or study participation. * history of neurological diseases or conditions that would affect the efficacy of nerve blocks (e.g., neuropathy, spinal cord injury, or history of severe muscle weakness).
Where this trial is running
Zagazig
- Faculity of medicine, Zagazig university, Zagazig — Zagazig, Egypt (Recruiting)
Study contacts
- Study coordinator: Dina Salem, MD
- Email: dinamaghraby@yahoo.com
- Phone: 0109933513
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.